Amarin Corp Plcuk (AMRN) EPS (Weighted Average and Diluted) (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported EPS (Weighted Average and Diluted) of -$0.03 for Q1 2026, up 25.0% year-over-year from -$0.02 in Q1 2025, and down 50.0% quarter-over-quarter from -$0.02 in Q3 2025.
Amarin Corp Plcuk (AMRN) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.03 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.03, up 25.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.08 (up 63.64% YoY), and the FY2025 annual result was -$0.09, up 55.0% from the prior year.
- EPS (Weighted Average and Diluted) fell to -$0.03 in Q1 2026 per AMRN's latest filing, from -$0.02 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.01 in Q4 2022 and troughed at -$0.18 in Q2 2022.
- A 5-year average of -$0.05 and a median of -$0.04 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) plunged 1841.64% in 2022, then soared 77.78% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.01 in 2022, then tumbled by 300.0% to -$0.02 in 2023, then tumbled by 500.0% to -$0.12 in 2024, then surged by 83.33% to -$0.02 in 2025, then tumbled by 50.0% to -$0.03 in 2026.
- Business Quant data shows AMRN's EPS (Weighted Average and Diluted) at -$0.03 in Q1 2026, -$0.02 in Q3 2025, and -$0.03 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.31 |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | -0.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.03 |
| Sep 30, 2025 | -0.02 |
| Jun 30, 2025 | -0.03 |
| Mar 31, 2025 | -0.04 |
| Dec 31, 2024 | -0.12 |
| Sep 30, 2024 | -0.06 |
| Mar 31, 2024 | -0.02 |
| Dec 31, 2023 | -0.02 |
| Sep 30, 2023 | -0.05 |
| Jun 30, 2023 | -0.04 |
| Mar 31, 2023 | -0.04 |
| Dec 31, 2022 | 0.01 |
| Sep 30, 2022 | -0.01 |
| Jun 30, 2022 | -0.18 |
| Mar 31, 2022 | -0.08 |
| Dec 31, 2021 | 0.04 |
| Sep 30, 2021 | -0.03 |
| Jun 30, 2021 | 0.02 |
| Mar 31, 2021 | 0.00 |
| Dec 31, 2020 | 0.01 |